Autoantibody against β1-adrenergic receptor and left ventricular remodeling changes in response to metoprolol treatment

European Journal of Clinical Investigation

Volumn 36, Issue 9, 2006, Pages 614-620

  Miao, G B ^a   Liu, J C ^a   Liu, M B ^a   Wu, J L ^a   Zhang, G ^a   Chang, J ^a   Zhang, L ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Anti 1 AR; Metoprolol; Target dosage; Titration; Tolerability

Indexed keywords

AUTOANTIBODY; BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR ANTIBODY; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; METOPROLOL; UNCLASSIFIED DRUG; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BETA ADRENERGIC RECEPTOR BLOCKING; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; DRUG DOSE REGIMEN; DRUG TOLERANCE; ECHOCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; BLOOD; DRUG ADMINISTRATION; DRUG EFFECT; EXERCISE TEST; HEART LEFT VENTRICLE FUNCTION; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; WALKING;

ADRENERGIC BETA-ANTAGONISTS; AUTOANTIBODIES; DRUG ADMINISTRATION SCHEDULE; EXERCISE TEST; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; METOPROLOL; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, ADRENERGIC, BETA-1; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING; WALKING;

EID: 33747033681     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2006.01705.x     Document Type: Article

References (27)

1. Di LA, Sabbadini G, Moretti M, Sinagra G. Long-term oral carvedilol in chronic heart failure. Expert Opin Pharmacother 2004;5:1359-72.
2. Milton P, Michael RB, Jay NC, Wilson SC, Michael BF, Edward MG et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
3. Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on mortality in patients with heart failure: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 1997;30:27-34.
4. The MDC trial study group. 3-year follow-up of patients randomised in the metoprolol in dilated cardiomyopathy trial. The Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1998;351:1180-1.
5. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13.
6. MERIT-HF study group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial Congestive Heart Failure (MERIT-HF). MERIT-HF Study Group. Lancet 1999;353:2001-7.
7. Metra M, Cas LD, Di LA, Poole-Wilson P. Beta-blockers in heart failure: are pharmacological differences clinically important? Heart Fail Rev 2004;9:123-30.
8. Kukin ML, Kalman J, Charney RH, Levy DK, Buchholz-Varley C, Ocampo ON et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999;99:2645-51.
9. Vantrimpont P, Rouleau JL, Wun CC, Ciampi A, Klein M, Sussex B et al. Additive beneficial effects of beta-blockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study: SAVE Investigators. J Am Coll Cardiol 1997;29:229-36.
10. Fu ML, Hoebeke J, Matsui S, Matoba M, Magnusson Y, Hedner T et al. Autoantibodies against cardiac G-protein-coupled receptors defines different populations with cardiomyopathies but not with hypertension. Clin Immunol Immunopathol 1994;72:15-20.
11. Zhang L, Hu D, Li J, Wu Y, Liu X, Yang X. Autoantibodies against the myocardial beta-1-adrenergic and M2-muscarinic receptors in patients with congestive heart failure. Chin Med J (Engl) 2002;115:1127-31.
12. Vatner DE, Asai K, Iwase M, Ishikawa Y, Shannon RP, Homcy CJ et al. Beta-adrenergic receptor-G protein-adenylyl cyclase signal transduction in the failing heart. Am J Cardiol 1999;83:H80-5.
13. Magnusson Y, Wallukat G, Waagstein F, Hjalmarson A, Hoebeke J. Autoimmunity in idiopathic dilated cardiomyopathy: characterization of antibodies against the beta-1-adrenoceptor with positive chronotropic effect. Circulation 1994;89:2760-7.
14. Matsui T, Persson M, Fu HM, Hayase M, Katsuda S, Teraoka K et al. Protective effect of bisoprolol on beta-1 adrenoceptor peptide-induced autoimmune myocardial damage in rabbits. Herz 2000;25:267-70.
15. Fu M, Matsui S. Is cardiomyopathy an autoimmune disease? Keio J M 2002;51:208-12.
16. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW et al. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132:919-23.
17. Fu ML, Hoebeke J, Matsui S, Matoba M, Magnusson Y, Hedner T et al. Autoantibodies against cardiac G-protein-coupled receptors define different populations with cardiomyopathies but not with hypertension. Clin Immunol Immunopathol 1994;72:15-20.
18. Freedman NJ, Lefkowitz RJ. Anti-beta-(1)-adrenergic receptor antibodies and heart failure: causation, not just correlation. J Clin Invest 2004;113:1379-82.
19. Zhang L, Hu DY, SHi XB, Li J, Zeng WJ, Xu L et al. Autoantibodies against the myocardium beta-1-adrenergic and M2-muscarinic receptors in patients with heart failure. Chin J Intern Med 2001;40:445-7.
20. Bristow MR. Beta-adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-69.
21. 1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nature Med 2003;9:1300-5.
22. Cleland JGF, Charlesworth A, Lubsen J, Swedberg K, Remme WJ, Erhardt L et al. For the COMET investigators: a comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the 'Patients Journey' in Patients with Heart Failure). J Am Coll Cardiol 2006;47:1603-11.
23. Braunwald E, Bristow MR. Congestive heart failure: fifty years of progress. Circulation 2000; 102: IV14-IV23.
24. Wallukat G, Nissen E, Morwinski R, Muller J. Autoantibodies against the beta-1 and muscarinic receptors in cardiomyopathy. Herz 2000;25:261-6.
25. Jahns R, Boivin V, Siegmund C, Inselmann G, Lohse MJ, Boege F. Autoantibodies activating human beta-1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 1999;99:649-54.
26. Mobini R, Fu M, Wallukat G, Magnusson Y, Hjalmarson A, Hoebeke J. A monoclonal antibody directed against an autoimmune epitope on the human beta-1-adrenergic receptor recognized in idiopathic dilated cardiomyopathy. Hybridoma 2000;19:135-42.
27. Lohse MJ, Engelhardt S, Eschenhagen T. What is the role of beta-adrenergic signaling in heart failure? Circ Res 2003;93:896-906.